Antimicrobial activity of cefoperazone/sulbactam
Cefoperazone/Sulbactam shows antimicrobial activity against ESBL-producing E. coli and K. pneumoniae organisms1
Cefoperazone/Sulbactam in patients with VAP due to CRAB strains
Adjunctive therapy with CEP-SUL+ had lower mortality rates and resource utilisation compared with CEP-SUL- in patients with VAP due to CRAB strains3
Adapted from Kanchanasuwan S, et al. 2021.
BL/BLIs in infections with ESBL-producing strains
Adapted from Sader HS, et al. 2020.
Adapted from Sader HS, et al. 2020.
*In patients using cefoperazone/sulbactam with or without combination with antimicrobial drugs, n=60. Combinations used were cefoperazone/sulbactam combined with minocycline, levofloxacin and meropenem.
AE, adverse event; APAC, Asia-Pacific; BL, beta-lactam; BLI, beta-lactamase inhibitor; CDAD, Clostridium difficile-associated diarrhoea; CEP-SUL−, patients who did not receive cefoperazone/sulbactam; CEP-SUL+, patients who received cefoperazone/sulbactam; CI, confidence interval; CRAB, carbapenem-resistant Acinetobacter baumannii; E-EU, Eastern Europe and Mediterranean; ESBL, extended-spectrum beta-lactamase; HAP, hospital-acquired pneumonia; LATAM, Latin America; RCT, randomised controlled trial; RR, risk ratio; VAP, ventilator-associated pneumonia; UTI, urinary tract infection; W-EU, Western Europe.
References:
Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of registered medical practitioner, or a hospital or a laboratory.
Cefoperazone/Sulbactam is recommended as an effective and well-tolerated antibiotic
Review efficacy profile
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.